142 related articles for article (PubMed ID: 32162400)
1. Assessment of tumor enhancement by contrast-enhanced CT in solid tumor-bearing dogs treated with toceranib phosphate.
Takagi S; Yamazaki H; Izumi Y; Hanazono K; Hoshino Y; Hosoya K
Vet Radiol Ultrasound; 2020 Jul; 61(4):427-434. PubMed ID: 32162400
[TBL] [Abstract][Full Text] [Related]
2. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F
Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
[TBL] [Abstract][Full Text] [Related]
3. Use of Toceranib Phosphate in the Treatment of Canine Bladder Tumors: 37 Cases.
Gustafson TL; Biller B
J Am Anim Hosp Assoc; 2019; 55(5):243-248. PubMed ID: 31433219
[No Abstract] [Full Text] [Related]
4. Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs.
Yamazaki H; Tanaka T; Mie K; Nishida H; Miura N; Akiyoshi H
J Vet Intern Med; 2020 May; 34(3):1272-1281. PubMed ID: 32267594
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study of proteinuria in dogs receiving toceranib phosphate.
Piscoya SL; Hume KR; Balkman CE
Can Vet J; 2018 Jun; 59(6):611-616. PubMed ID: 29910474
[TBL] [Abstract][Full Text] [Related]
6. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma.
Rippy SB; Gardner HL; Nguyen SM; Warry EE; Portela RA; Drost WT; Hostnik ET; Green EM; Chew DJ; Peng J; London CA
BMC Vet Res; 2016 Nov; 12(1):257. PubMed ID: 27855679
[TBL] [Abstract][Full Text] [Related]
8. Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs.
Tjostheim SS; Stepien RL; Markovic LE; Stein TJ
J Vet Intern Med; 2016 Jul; 30(4):951-7. PubMed ID: 27149912
[TBL] [Abstract][Full Text] [Related]
9. Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma.
Musser ML; Johannes CM
BMC Vet Res; 2021 Aug; 17(1):269. PubMed ID: 34380474
[TBL] [Abstract][Full Text] [Related]
10. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
London C; Mathie T; Stingle N; Clifford C; Haney S; Klein MK; Beaver L; Vickery K; Vail DM; Hershey B; Ettinger S; Vaughan A; Alvarez F; Hillman L; Kiselow M; Thamm D; Higginbotham ML; Gauthier M; Krick E; Phillips B; Ladue T; Jones P; Bryan J; Gill V; Novasad A; Fulton L; Carreras J; McNeill C; Henry C; Gillings S
Vet Comp Oncol; 2012 Sep; 10(3):194-205. PubMed ID: 22236194
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
[TBL] [Abstract][Full Text] [Related]
12. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.
Laver T; London CA; Vail DM; Biller BJ; Coy J; Thamm DH
Vet Comp Oncol; 2018 Mar; 16(1):E23-E29. PubMed ID: 28621057
[TBL] [Abstract][Full Text] [Related]
14. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.
Weishaar KM; Ehrhart EJ; Avery AC; Charles JB; Elmslie RE; Vail DM; London CA; Clifford CA; Eickhoff JC; Thamm DH
J Vet Intern Med; 2018 Jan; 32(1):394-405. PubMed ID: 29194765
[TBL] [Abstract][Full Text] [Related]
15. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
Chon E; McCartan L; Kubicek LN; Vail DM
Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941
[TBL] [Abstract][Full Text] [Related]
16. Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.
Yamazaki H; Miura N; Lai YC; Takahashi M; Goto-Koshino Y; Yasuyuki M; Nakaichi M; Tsujimoto H; Setoguchi A; Endo Y
J Vet Med Sci; 2017 Jul; 79(7):1225-1229. PubMed ID: 28592719
[TBL] [Abstract][Full Text] [Related]
17. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
Pan X; Tsimbas K; Kurzman ID; Vail DM
Vet Comp Oncol; 2016 Jun; 14(2):202-9. PubMed ID: 24735385
[TBL] [Abstract][Full Text] [Related]
18. Increased incidence of gastrointestinal toxicity in canine cancer patients treated with concurrent abdominal radiation therapy and toceranib phosphate.
Prebble AR; Weishaar KM; Thamm DH; Leary D; LaRue SM; Martin T; Boss MK
Vet Comp Oncol; 2022 Mar; 20(1):142-153. PubMed ID: 34310002
[TBL] [Abstract][Full Text] [Related]
19. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
[TBL] [Abstract][Full Text] [Related]
20. Successful management of lymphangiosarcoma in a puppy using a tyrosine kinase inhibitor.
Kim JH; Yoon H; Yoon HY; Eom K; Sung HJ; Kim JH
Can Vet J; 2018 Apr; 59(4):367-372. PubMed ID: 29606721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
